Allogeneic bone marrow transplantation with non-T-cell-depleted marrow from two HLA-antigen-mismatched related donors

Haematologica

Volumn 89, Issue 3, 2004, Pages 373-375

  Ogawa, Hiroyasu ^a   Ikegame, Kazuhiro ^a   Kawakami, Manabu ^a   Taniguchi, Yuki ^a   Oka, Yoshihiro ^a   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Graft versus host disease; HLA mismatched BMT; Methylprednisolone; Tacrolimus

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; DONOR; DRUG EFFICACY; DRUG INFUSION; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; JAPAN; LYMPHOCYTE DEPLETION; MALE; RASH; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADULT; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; LYMPHOCYTE DEPLETION; MALE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 2942744297     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Ogawa H, Soma T, Hosen N, Tatekawa T, Tsuboi A, Oji Y, et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation, 2002;74:236-43.
2. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997;15:1767-77.
3. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990;29:79-91.
4. Anasetti C, Hansen JA. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 1994;15:221-30.
5. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
6. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814-9.